PB0089 - Clinical assessment of coagulation hemostasis in liver cirrhosis associated with COVID-19

Sunday, July 10, 2022

6:30 PM – 7:30 PM

Location: Exhibition

Presentation Format: In-Person

Presenting Author(s)

Marufjon Salokhiddinov, MD

Head of Palliate Care Department
Zangiota-2 COVID Specialized Centre
Tashkent, Toshkent, Uzbekistan

Co-Author(s)

OM

Otabek Muminov

Head of Clinical Laboratory Department
Zangiota 2 COVID Specialized Hospital
Tashkent, Qashqadaryo, Uzbekistan
ZQ

Zumrad Qurbanova

Research fellow of Clinical Laboratory department
Zangiota 2 COVID Specialized Hospital
Tashkent, Toshkent, Uzbekistan

Background: Since the beginning of the pandemic, our understanding of the hepatic repercussions of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 has significantly progressed.

Aims: The primary objective of this study was to characterize coagulation hemostasis in patients with COVID-19-associated liver cirrhosis.

Methods: Our study involved 200 patients (confirmed COVID-19 ) with liver cirrhosis, decompensation stage, Child-Pugh class V as the objects of study. I group consisted of 50 patients with liver cirrhosis of HBV etiology, II group 30 patients with HBV + HDV liver cirrhosis, III groups 50 patients with cirrhosis of unknown etiology. The control group consisted of 20 healthy individuals. All patients were tested for coagulogram.

Results: In group I, activated partial thromboplastin time was 18.4 ± 2.3 c, prothrombin time was 9.5 ± 0.6 c, prothrombin index was 126 ± 6.4, and MNO was 0.79 ± 0.03. In group II, activated partial thromboplastin time was 15.2 ± 1.1 c, prothrombin time was 8.2 ± 0.4 c, prothrombin index was 146 ± 8.2, and the international normalized ratio was 0.68 ± 0.02. In group III, was 12.2 ± 0.8 c, prothrombin time was 7.9 ± 0.4 c, prothrombin index was 152 ± 10.4, and the international normalized ratio was 0.66 ± 0.02. In the control group, activated partial thromboplastin time was 32 ± 1.8 c, prothrombin time was 12.1 ± 0.2 c, prothrombin index was 99 ± 3.7, and the international normalized ratio was 1.01 ± 0.06.

Conclusion(s): To summarize, our findings demonstrate that severe COVID-19 infection is associated with coagulopathy, which is associated with a bad prognosis. COVID-19 coagulopathy, on the other hand, does not appear to be a form of disseminated intravascular coagulation. Additional research is required to elucidate additional probable mechanisms of this coagulopathy, including a thorough examination of the fibrinolytic system.